Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Eligible patients will be prescribed Desloratadine 1 tablet of 5 mg once daily. Patients will be asked to follow-up for a final visit after 14 days (Day 15) where the safety, tolerability and clinical efficacy will be measured.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group | Patients diagnosed with Allergic Rhinitis or Chronic Idiopathic Urticaria |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Desloratadine | Drug | Desloratadine 5 mg once daily |
|
|
| Measure | Description | Time Frame |
|---|---|---|
| Adverse Events | Number of adverse events reported | Final Visit (Day 15) |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Filipino patients diagnosed to have Allergic Rhinitis or Chronic Idiopathic Urticaria
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Desloratadine | Desloratadine 5 mg daily |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Desloratadine | Desloratadine 5 mg daily |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Adverse Events | Number of adverse events reported | Posted | Number | adverse events reported | Final Visit (Day 15) |
|
|
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Head, Clinical Trials Registry & Results Disclosure Group | Schering-Plough | ClinicalTrialsDisclosure@spcorp.com |
Not provided
| ID | Term |
|---|---|
| D012220 | Rhinitis |
| D014581 | Urticaria |
| ID | Term |
|---|---|
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
| D009668 | Nose Diseases |
| D012140 | Respiratory Tract Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C121345 | desloratadine |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Lost to Follow-up |
|
| No Info |
|
| Participants |
|
| Sex: Female, Male | Count of Participants | Participants |
|
|
The PI agree only to use such information to conduct the study and will not be able to publish the results of any part of the study without previous writeen authorization from Schering-Plough.
| D010038 |
| Otorhinolaryngologic Diseases |
| D017445 | Skin Diseases, Vascular |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D006969 | Hypersensitivity, Immediate |
| D006967 | Hypersensitivity |
| D007154 | Immune System Diseases |